https://www.selleckchem.com/pr....oducts/tlr2-in-c29.h
moderate to low-certainty evidence. More data are needed for the longer-term efficacy of belimumab. To assess the teratogenic risk of domperidone by comparing the incidence of major malformation with domperidone to a control. Pregnancy outcome data were obtained for women at two Japanese facilities that provide counseling on drug use during pregnancy between April 1988 and December 2017. The incidence of major malformation was calculated among infants born to women taking domperidone (n = 519), nonteratogenic drugs (control, n = 167
Aimer
Commentaire
Partagez
